Duration of Efficacy Increases with the Repetition of Botulinum Toxin A Injections in Primary Axillary Hyperhidrosis: A 15-year Study in 117 Patients

Berthin, C.; Maillard, H.

doi:10.2340/00015555-3307

Cited by 6 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They speculated that the increase in duration and efficacy of injection repetitions were related to the gradual regeneration of the axon terminal of the motor neuron. Berthin and Maillard recently confirmed these findings with a retrospective 15-years study on 117 patients [29].…”

Section: Resultssupporting

confidence: 53%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Resultssupporting

confidence: 53%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…Interestingly, two previous studies have shown that the duration of efficacy of BoNT-A treatment for axillary hyperhidrosis increases with treatment repetition. 16,17 In conclusion, abobotulinum toxin-A is more frequently used in daily practice because it is more cost-effective. Facial wrinkles, platysmal bands, and masseter hypertrophy are the most commonly desired-to-be-treated areas.…”

Section: Discussionmentioning

confidence: 99%

A retrospective analysis of the uses of BoNT‐A in daily dermatological practice

Hugul

Özkoca

Kutlubay

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…These data are similar to those reported for BoNT injections for the treatment of hyperhidrosis. During long-term follow-up, it was found that repeated injections increased the duration of efficacy by more than 50% [26]. Further longterm studies are required to identify the duration of response in subjects with sialorrhea.…”

Section: Discussionmentioning

confidence: 99%

Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks

Jost

Friedman

Michel

et al. 2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Background: Botulinum neurotoxin (BoNT) is an effective treatment for chronic sialorrhea; however, reliable and robust evidence supporting long-term efficacy and safety is lacking. This study investigated the efficacy and safety of repeated incobotulinumtoxinA injections for chronic sialorrhea over 64 weeks. Methods: Adults with sialorrhea were randomized (2:2:1) to incobotulinumtoxinA 75 U, incobotulinumtoxinA 100 U (n = 74 each), or placebo (n = 36) in the double-blind, placebo-controlled main period (NCT02091739). Eligible subjects entered the extension period and received dose-blinded incobotulinumtoxinA 75 or 100 U in three further 16±2-week injection cycles. Efficacy and safety assessments in subjects who received incobotulinumtoxinA throughout the study included unstimulated salivary flow rate (uSFR), subjects' Global Impression of Change Scale (GICS), Drooling Severity and Frequency Scale (DSFS), modified Radboud Oral Motor Inventory for Parkinson's Disease (mROMP) drooling, speech, and swallowing symptom scores, and incidence of adverse events (AEs). Results: In total, 173/184 subjects (94%) completed the main period and entered the extension period; 141 subjects received incobotulinumtoxinA 75 U (n = 69) or 100 U (n = 72) in both periods. Mean uSFR decreased consistently with repeated incobotulinumtoxinA 75 and 100 U treatment and by −0.16 and −0.17, respectively, at the end-of-study visit. Subjects' GICS, DSFS, and mROMP drooling scores also improved at all assessments. mROMP speech and swallowing scores remained stable. The most common treatment-related AEs during the extension period were dry mouth (4.4% and 11.1%) and dysphagia (1.5% and 4.2%). Conclusions: Data support long-term efficacy and safety of repeated incobotulinumtoxinA treatment for sialorrhea, with no additional safety concerns reported over 64 weeks.

show abstract

Duration of Efficacy Increases with the Repetition of Botulinum Toxin A Injections in Primary Axillary Hyperhidrosis: A 15-year Study in 117 Patients

Abstract: Future studies could focus on patients with a decrease in DE, in order to identify the risk factors for the type of this evolution or the differences between responder and non-responder patients.

Cited by 6 publications

References 17 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

A retrospective analysis of the uses of BoNT‐A in daily dermatological practice

Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks

Contact Info

Product

Resources

About